Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Genmab A/S

Market Cap 99.4B 15.4B 13.3B 12.26B 11.47B 21.5B 1,464B 21.84B 145B 56.44B 713B 57.81B 56.57B 2,467B P/E Ratio 2026 *
21.4x
P/E Ratio 2027 * 14.9x
Enterprise Value 119B 18.42B 15.91B 14.66B 13.73B 25.72B 1,751B 26.12B 173B 67.5B 852B 69.14B 67.67B 2,951B EV / Sales 2026 *
4.3x
EV / Sales 2027 * 3.45x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.63%
1 week-0.28%
Current month-4.75%
1 month-7.42%
3 months-5.61%
6 months-19.90%
Current year-18.57%
1 week 24.46
Extreme 24.455
25.38
1 month 23.62
Extreme 23.62
27.36
Current year 23.62
Extreme 23.62
35.43
1 year 20.22
Extreme 20.225
35.43
3 years 17.24
Extreme 17.235
42.72
5 years 17.24
Extreme 17.235
49.07
10 years 12.1
Extreme 12.1
49.07
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-0.28% - - 15.4B
+1.03%+2.30%+54.92%+111.78% 56.42B
+2.72%+3.26%+47.26%+47.26% 44.54B
+1.12%+2.79%-13.71%-17.53% 22.9B
+1.17%+3.85%+1.00%+401.79% 21.21B
+3.81%-5.07%+12.00%-29.52% 16.4B
-0.69%+0.82%+27.17%+178.31% 13.35B
+5.27%+5.54%+14.25% - 12.36B
+1.61%+1.28%+92.88%+215.31% 11.15B
+1.37%-1.28%+61.76%+80.92% 11.08B
Average +1.68%+1.70%+33.06%+123.54% 23.27B
Weighted average by Cap. +1.65%+2.18%+35.18%+110.26%

Financials

2026 *2027 *
Net sales 27.65B 4.28B 3.7B 3.41B 3.19B 5.98B 407B 6.07B 40.26B 15.7B 198B 16.08B 15.74B 686B 32.41B 5.02B 4.34B 4B 3.74B 7.01B 477B 7.12B 47.2B 18.4B 232B 18.85B 18.45B 805B
Net income 4.71B 730M 631M 581M 544M 1.02B 69.4B 1.04B 6.86B 2.68B 33.78B 2.74B 2.68B 117B 7.02B 1.09B 939M 866M 810M 1.52B 103B 1.54B 10.22B 3.99B 50.32B 4.08B 4B 174B
Net Debt 19.49B 3.02B 2.61B 2.4B 2.25B 4.22B 287B 4.28B 28.39B 11.07B 140B 11.34B 11.1B 484B 12.47B 1.93B 1.67B 1.54B 1.44B 2.7B 184B 2.74B 18.16B 7.08B 89.42B 7.25B 7.1B 310B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,088
Date Price Change Volume
12/06/26 25.08 $ -0.63% 1,113,721
11/06/26 25.24 $ +3.06% 1,173,452
10/06/26 24.49 $ -2.43% 876,185
09/06/26 25.10 $ +1.21% 1,329,445
08/06/26 24.80 $ -1.39% 1,435,931
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,619.00DKK
Average target price
2,313.13DKK
Spread / Average Target
+42.87%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!